Discover the Evexia advantage Start ordering today
Take advantage of all the time and money-saving features that Evexia Diagnostics has to offer. Simply click the button below to get started.
Register Now
Welcome to the Evexia Diagnostics
COVID-19 Repository Page.
While the global health crisis concerning the SARS-CoV-2 pandemic continues to unfold, Evexia’s focus and commitment to offering high-quality, state-of-the-art testing at affordable prices are becoming increasingly vital. Our current goal is to increase the availability of fast and reliable COVID-19 testing to help mitigate the current spread of the virus. We also recognize that there is a lack of proper guidance on what testing is most appropriate. As a result, we have created this resource dedicated to providing easy access to insightful information, cost-effective and reliable testing options, as well as recommendations for nutraceutical support.
COVID-19 Testing Guidance
Although much has changed since the COVID-19 pandemic began and multiple vaccines are now available, testing for the SARS-CoV-2 virus remains a critical component to ensuring health and safety. Many questions continue to remain regarding the SARS-CoV-2 virus and the body’s immune response. This guide is intended to offer some basic insight into the testing available through Evexia Diagnostics and which test would be most applicable depending on the patient’s circumstances.
My patient already had COVID-19 but wants to know if they have antibodies.
Recommended Testing Options:
My patient has been vaccinated and wants to know if they are protected.
Recommended Testing Options:
My patient is not feeling well and wants to know if they have COVID-19.
My patient is going to be traveling and needs testing.
Recommended Testing Options:
My patient is returning to work/school and needs testing.
Recommended Testing Options:
SARS CoV-2 Diagnostic Respiratory PCR Test – Click here
Diagnostic Testing
SARS CoV-2 Diagnostic Respiratory PCR Test
- Diagnostic test for SARS-CoV-2, using real-time reverse transcriptase polymerase chain reaction (RT-PCR) technology
- Detects the presence of SARS-CoV-2 viral RNA in respiratory samples
- Determines current SARS-CoV-2 infection but does not indicate past infection or immunity
- Utilizes Nasal or Nasopharyngeal swab
- Rapid 24-48 hour turnaround time kit
SARS CoV-2 Diagnostic Salivary PCR Test
- Diagnostic test for SARS-CoV-2, using real-time reverse transcriptase polymerase chain reaction (RT-PCR) technology
- Detects the presence of SARS-CoV-2 viral RNA in salivary samples
- Determines current SARS-CoV-2 infection but does not indicate past infection or immunity
- Utilizes simple at-home salivary collection
- Rapid 24-48 hour turnaround time
The United States FDA has provided emergency use authorization (EUA) of this test for testing human upper and lower respiratory specimens
Flowflex COVID-19 Antigen Home Test
- Rapid Antigen Home Test is a lateral flow immunochromatographic assay for the detection of extracted nucleocapsid protein antigens specific to SARS-CoV-2, not for any other viruses or pathogens.
- For use with direct anterior nasal and nasopharyngeal swab specimens, non-invasive test procedures
- Detect SARS-CoV-2 nucleocapsid protein antigen
- Accuracy:
- Nasal Swab: 98.8% (95% CI: 97.6%-99.5%) 95% Confidence Intervals
- Saliva: 97.1% (95% CI: 94.6%-98.5%) 95% Confidence Intervals
- Variant-ready solution
- Rapid results within 15 minutes
The United States FDA has provided emergency use authorization (EUA) of this test for testing human upper and lower respiratory specimens
Quidel Quickvue At Home OTC COVID-19 Tests (25 dipsticks per box)
This item is packaged as 1 bulk box that contains 25 single dipsticks in a tube.
The QuickVue At-Home OTC COVID-19 Test is intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 from individuals with or without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 36 hours between tests. This test is authorized for nonprescription home use with self-collected (unobserved) direct anterior nasal (NS) swab specimens from individuals aged 14 years and older or with adult-collected anterior NS samples from individuals aged 2 years or older.
The QuickVue At-Home OTC COVID-19 Test does not differentiate between SARS-CoV and SARS-CoV-2.
COVID-19 Immune Response Panel
Serum test that measures both nucleocapsid (N-protein) and S-RBD antibodies
The COVID-19 Immune Response Panel measures both nucleocapsid (N-protein) and S-RBD antibodies. N-protein antibodies do not rise in response to COVID-19 S-RBD vaccinations. The combined serum IgM/IgG tests measure the body’s response to COVID-19 nucleocapsid (N) and spike protein receptor-binding domain (S-RBD) exposure. The N and S-RBD antibodies’ combination assay has a > 99% positive and negative predictive value 15 days after COVID-19 exposure. This test does not differentiate between IgM and IgG; studies indicate that joint testing is as or more reliable than individual IgM and IgG testing in confirming COVID-19 exposure.
COVID-19 Vaccine Response Screen
Serum test which measures only the antibody response to the S-RBD protein
The COVID-19 Vaccine Response Screen measures only the antibody response to the S-RBD protein. Once the baseline immune response has been established, this test can be used post-vaccination to evaluate immune status. The average time for seroconversion has been estimated at 2-3 weeks. However, the strongest antibody responses will likely be seen after the second vaccine dose 6-8 weeks after the first inoculation.
SARS-CoV-2 Quantitative IgG & IgM Antibody Panel
- Serological detection of IgG and IgM antibodies to identify exposure to the SARS-CoV-2 virus, regardless of symptom presentation
- Evaluation of IgG and IgM reactivity separately, providing individual results for each and may be useful for determining the current stage of infection
- Testing is performed on a high-precision chemiluminescent immunoassay that has received FDA authorization under emergency use authorization (EUA)
- Highly sensitive technology can detect even very small amounts of IgM and IgG antibodies for SARS-CoV-2
- In a human study of COVID-19 patients, the IgG + IgM Antibody Panel was found to meet the following specifications for sensitivity and clinical specificity:
-IgG:
100% Sensitivity
97.4% Specificity
@ >15 days post-infection
-IgM:
94.4% Sensitivity
98.3% Specificity
@ >15 days post-infection - 95% of results available in 24-hours
To learn more about Antibody Testing – Click Here • To learn more about Antibodies – Click Here
COVID-19 Antibody Testing
- NOT A DIAGNOSTIC TEST FOR CURRENT COVID-19 INFECTION
- Detects body’s immune response to COVID-19 by measuring specific antibodies associated with COVID-19 (SARS-CoV-2)
- Any positive results should be confirmed using the COVID-19 PCR Test.
- Follow-up testing with the COVID-19 PCR Test should also be considered to rule out infection in individuals with a negative COVID-19 Antibody Test who exhibit symptoms of COVID-19
- Blood draw required
COVID-19 Antibody Testing is available to all Evexia clients, including non-licensed clinicians. For all non-licensed client orders, a $15 physician network fee will apply and our phlebotomy network must be utilized for sample collection and shipping.
IgA Antibodies
- IgA antibodies are found in saliva, tears, and blood.
- IgA antibodies protect bodily surfaces that are exposed to outside foreign substances and are found in areas of the body such as the nose, breathing passages, digestive tract, ears, and eyes.
- About 10% to 15% of the antibodies present in the body are IgA antibodies.
- A small number of people do not make IgA antibodies.
IgG Antibodies
- IgG antibodies are found in all body fluids.
- IgG antibodies are the smallest but most common antibody (75% to 80%).
- IgG antibodies are very important in fighting bacterial and viral infections.
- IgG antibodies are the only type of antibody that can cross the placenta in a pregnant woman to help protect the fetus.
IgM Antibodies
- IgM antibodies are found in blood and lymph fluid and are the first type of antibody made in response to an infection.
- IgM antibodies also cause other immune system cells to destroy foreign substances.
- IgM antibodies are the largest antibody and make up about 5% to 10% of all the antibodies in the body.
Please note that negative results do not rule out SARS-CoV-2 infection. Results from the COVID-19 Antibody Test should not be used as the sole basis for diagnosis or exclusion of a SARS-CoV-2 infection. Follow-up testing with the COVID-19 PCR test should be considered to rule out infection in individuals with negative serological results who exhibit symptoms of COVID-19.
Evexia Diagnostics does not accept any form of insurance nor do we have the ability to seek third-party reimbursement. We are offering this test as a convenience to our clients and their patients, who may not be able or may choose not to travel to a location where the test can be charged to a third-party. The fees charged by Evexia to our clients for the COVID-19 test are a reflection of our cost related to the acquisition and distribution of the COVID-19 test and supplies. Anyone who is symptomatic and/or who meets the CDC’s guidelines for testing has the option of receiving the test for free, but they would need to locate a testing facility (clinic, drive-thru or hospital) that is able to seek 3rd-party reimbursement and have the testing done there.
The Evexia Webinar Series Special Edition
David M. Brady,
ND, DC, CCN, DACBN, IFMCP, FACN
Chief Medical Officer Diagnostic Solutions Laboratory
Evexia Diagnostics is excited to present a special edition webinar with Dr. David Brady from Diagnostic Solutions Laboratory. The topic will be COVID-19: What we know now, and making informed choices moving forward.
Wayne L. Sodano,
DC, DABCI, DACBN, CFMP, CIHP, BCTN
Director of Clinical Support and Education Evexia Diagnostics
Contributors:
Kevin K. Bodling,
DC, DACBN, DABCI President & Chief Executive Officer Evexia Diagnostics
Will Blankenship, MD
Chief Medical Officer
Evexia Diagnostics
Evexia Diagnostics is pleased to present “COVID-19: Immune Preparedness Against An Unfolding Pandemic”. This video serves as a follow up to our previous COVID-19 webinar and provides some updated information, but more importantly, offers an in-depth look at avenues to improve immune function and help prevent infection.
Wayne L. Sodano,
DC, DABCI, DACBN, CFMP, CIHP, BCTN
Director of Clinical Support and Education Evexia Diagnostics
Contributors:
Kevin K. Bodling, DC, DACBN, DABCI
President & Chief Executive Officer
Evexia Diagnostics
Will Blankenship, MD
Chief Medical Officer
Evexia Diagnostics
The underlying importance of a properly functioning immune system is highlighted as global concerns continue to grow regarding the spread of COVID-19 (Coronavirus Disease). Evexia Diagnostics is proud to offer an educational webinar for you to learn more about the natural avenues and precautionary measures available to help safeguard against infection and to help ensure that your patient’s immune system is able to provide an adequate response to this emerging threat.
Disclaimer: This webinar is for professional educational purposes only. Currently there are no pharmaceutical or natural medicines approved by the FDA to specifically treat COVID-19.
Recommended Evexia Nutraceuticals and Supplements
Currently there are no pharmaceutical or natural medicines
approved by the FDA to specifically treat COVID-19.